New hope for Tough-to-Treat lung cancer spread to the brain
NCT ID NCT07361705
Summary
This early-stage study is testing whether adding a new drug called zorifertinib to an existing cancer drug (osimertinib) is safe and effective. It is for people with advanced lung cancer where the disease has spread to the membranes around the brain and spinal cord, and has worsened despite current treatment. The main goal is to find the right dose and see if the combination can help control this difficult-to-treat cancer spread.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WITH MENINGEAL PROGRESSION AFTER OSIMERTINIB TREATMENT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.